Betaine; a potential agent for the treatment of hepatopathy associated with short bowel syndrome;Betaína; un agente potencial para el tratamiento de la hepatopatía asociada con el síndrome del intestino corto

Nutricion Hospitalaria

Volumn 29, Issue 6, 2014, Pages 1366-1371

  de Araújo, Guilherme Teixeira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Betaine; Hepatic steatosis; Homocysteine; Magnetic resonance; Short bowel syndrome

Indexed keywords

BETAINE; GASTROINTESTINAL AGENT;

ADULT; AGED; CLINICAL TRIAL; COMPLICATION; FATTY LIVER; FEMALE; HUMAN; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDY; SHORT BOWEL SYNDROME; YOUNG ADULT;

ADULT; AGED; BETAINE; FATTY LIVER; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SHORT BOWEL SYNDROME; YOUNG ADULT;

EID: 84903538967     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2014.29.6.7378     Document Type: Article

References (30)

1. Kemp R, Correia RB, Sankarankutty AK, dos Santos JS, Módena JL, Mente ED, Silva Ode C. Liver disease associated with intestinal failure in the small bowel syndrome. Acta Cir Bras 2006; 21 (Supl. 1): 67-71.
2. O'Keefe SJ, Buchman AL, Fishbein TM, Jeejeebhoy KN, Jeppesen PB, Shaffer J. Short bowel syndrome and intestinal failure: consensus definitions and overview. Clin Gastroenterol Hepatol 2006; 4 (1): 6-10.
3. Wang MY, Wu MH, Hsieh DY, Lin LJ, Lee PH, Chen WJ, Lin MT. Home Parenteral Nutrition Support in Adults: Experience of a Medical Center in Asia. JPEN J Parenter Enteral Nutr 2007; 31: 306.
4. Staun M, Hebuterne X, Shaffer J, Haderslev KV, Bozzetti F, Pertkiewicz M, Micklewright A, Moreno J, Thul P, Pironi L. Management of intestinal failure in Europe. A questionnaire based study on the incidence and management. Dyn Med 2007; 4 (6): 7.
5. Kelly DA. Intestinal failure-associated liver disease: what do we know today? Gastroenterology 2006; 130 (Supl. 1): S70-7.
6. Moreno Villares JM. Complicaciones hepáticas asociadas al uso de nutrición parenteral. Nutr Hosp 2008; 23 (Supl. 2): 25-33.
7. Diamanti A, Basso MS, Castro M, Di Ciommo V, Bracci F, Ferretti F, Pietrobattista A, Gambarara M. Irreversible intestinal failure: prevalence and prognostic factors. J Pediatr Gastroenterol Nutr 2008; 47 (4): 450-7.
8. Chan S, McCowen KC, Bistrian BR, Thibault A, Keane-Ellison M, Forse RA, Babineau T, Burke P. Incidence, prognosis, and etiology of end-stage liver disease in patients receiving home total parenteral nutrition. Surgery 1999; 126: 28-34.
9. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132: 525-32.
10. Spurr SG, Grylack LJ, Mehta NR. Hyperalimentation-associated neonatal cholestasis: effect of oral gentamicin. J Parenter Enteral Nutr 1989; 13: 633-6.
11. Kubota A, Okada A, Imura K, Kawahara H, Nezu R, Kamata S, Takagi Y. The effect of metronidazole on TPN-associated liver dysfunction in neonates. J Pediatr Surg 1990; 25: 618-21.
12. Markley MA, Pierro A, Eaton S. Hepatocyte mitochondrial metabolism is inhibited in neonatal rat endotoxaemia: effects of glutamine. Clin Sci 2002; 102: 337-44.
13. Levine A, Maayan A, Shamir R, Dinari G, Sulkes J, Sirotta L. Parenteral nutrition-associated cholestasis in preterm neonates. Evaluation of ursodeoxycholic acid treatment. J Pediatr Endocrinol Metab 1999; 12: 549-53.
14. Trauner M, Graziadei IW. Review article. mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999; 13: 979-95.
15. Teitelbaum DH, Han-MarkeyY T, Schumacher RE. Treatment of parenteral nutrition-associated cholestasis with cholecystokininoctapeptide. J Pediatr Surg 1995; 30: 1082-5.
16. Teitelbaum DH, Tracy TF Jr, Aouthmany MM, Llanos A, Brown MB, Yu S, Brown MR, Shulman RJ, Hirschl RB, Derusso PA, Cox J, Dahlgren J, Groner JI, Strouse PJ. Use of cholecystokininoctapeptide for the prevention of parenteral nutrition-associated cholestasis. Pediatrics 2005; 115: 1332-40.
17. Piper SN, Schade I, Beschmann RB, Maleck WH, Boldt J, Röhm KD. Hepatocellular integrity after parenteral nutrition: comparison of a fish-oil-containing lipid emulsion with an olive-soybean oil-based lipid emulsion. Eur J Anaesthesiol 2009; 26 (12): 1076-82.
18. de Meijer VE, Gura KM, Le HD, Meisel JA, Puder M. Fish oilbased lipid emulsions prevent and reverse parenteral nutritionassociated liver disease: the Boston experience. J Parenter Enteral Nutr 2009t; 33 (5): 541-7.
19. Grant D. Intestinal transplantation: 1997 report of the international registry. Transplantation 1999; 67: 1061-4.
20. Brook G. Quality of life issues; parenteral nutrition to small bowel transplantation-a review. Nutrition 1998; 14: 813-6.
21. Van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, Stoker J. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010; 256 (1): 159-68.
22. Schwahn BC, Hafner D, Hohlfeld T, Balkenhol N, Laryea MD, Wendel U. Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria. Br J Clin Pharmacol 2003; 55: 6-13.
23. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96 (9): 2711-7.
24. Abdelmalek MF, Sanderson SO, Angulo P, Soldevila-Pico C, Liu C, Peter J, Keach J, Cave M, Chen T, McClain CJ, Lindor KD. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009; 50 (6): 1818-26.
25. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A doubleblind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000; 50 (8): 722-7.
26. Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39: 619-25.
27. Olthof MR, van Vliet T, Boelsma E, Verhoef P. Low dose betaine supplementation leads to immediate and long term lowering of plasma homocysteine in healthy men and women. J Nutr 2003; 133: 4135-8.
28. Friedrich-Rust M, Müller C, Winckler A, Kriener S, Herrmann E, Holtmeier J, Poynard T, Vogl TJ, Zeuzem S, Hammerstingl R, Sarrazin C. Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers. J Clin Gastroenterol 2010; 44 (1): 58-65.
29. Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway. J Hepatol 2007; 46 (2): 314-21.
30. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006 Apr; 83 (4): 735-43.